Delving into the Latest Updates on Fluorothymidine F-18 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

+ [1]

Target-

Action

enhancers

Mechanism

PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [1]

Active Indication

Acute Lymphoblastic LeukemiaBrain Cancer

Inactive Indication

Acute Myeloid LeukemiaAdvanced cancerAdvanced Head and Neck Carcinoma+ [27]

Originator Organization

National Cancer Institute

Active Organization

The Children's Hospital Corp.

Advanced Innovative Partners Inc

Inactive Organization

National Cancer Institute

National Institutes of Health

The University of Texas Southwestern Medical Center

+ [3]

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS Registry287114-80-1

This phase 1/2 trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) (phase 1) or patients with leiomyosarcoma or dedifferentiated liposarcoma (phase 2). Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Giving abemaciclib with gemcitabine may be safe and effective when compared to treatment with gemcitabine and docetaxel for patients with advanced or metastatic soft tissue sarcoma or leiomyosarcoma or dedifferentiated liposarcoma.

Start Date14 Oct 2025

Sponsor / Collaborator

National Cancer Institute

NCT03633955

/ RecruitingPhase 1IIT

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

Start Date19 Jan 2023

Sponsor / Collaborator

University of Oklahoma

[+1]

NCT04221438

/ Active, not recruitingPhase 2IIT

A Phase II Neoadjuvant Study of Encorafenib With Binimetinib in Patients With Resectable Locoregional Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)

This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib may provide more information on melanoma over time.

Start Date22 Sep 2021

Sponsor / Collaborator

ECOG-ACRIN Medical Research Foundation, Inc.

[+1]

100 Clinical Results associated with Fluorothymidine F-18

Login to view more data

100 Translational Medicine associated with Fluorothymidine F-18

Login to view more data

100 Patents (Medical) associated with Fluorothymidine F-18

Login to view more data

519

Literatures (Medical) associated with Fluorothymidine F-18

15 Apr 2024·Clinical Cancer Research

Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging

Article

Author: Soloviev, Dmitry ; Mackintosh, Agata ; Bielik, Robert ; Campbell, Andrew ; Malviya, Gaurav ; Nixon, Colin ; Lewis, David Y ; Johnson, Emma ; Peters, Adam ; Gilroy, Kathryn ; Lannagan, Tamsin R M ; Brown, Gavin ; Sansom, Owen J ; Jackstadt, Rene

AbstractPurpose:The current approach for molecular subtyping of colon cancer relies on gene expression profiling, which is invasive and has limited ability to reveal dynamics and spatial heterogeneity. Molecular imaging techniques, such as PET, present a noninvasive alternative for visualizing biological information from tumors. However, the factors influencing PET imaging phenotype, the suitable PET radiotracers for differentiating tumor subtypes, and the relationship between PET phenotypes and tumor genotype or gene expression–based subtyping remain unknown.Experimental Design:In this study, we conducted 126 PET scans using four different metabolic PET tracers, [18F]fluorodeoxy-D-glucose ([18F]FDG), O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET), 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), and [11C]acetate ([11C]ACE), using a spectrum of five preclinical colon cancer models with varying genetics (BMT, AKPN, AK, AKPT, KPN), at three sites (subcutaneous, orthograft, autochthonous) and at two tumor stages (primary vs. metastatic).Results:The results demonstrate that imaging signatures are influenced by genotype, tumor environment, and stage. PET imaging signatures exhibited significant heterogeneity, with each cancer model displaying distinct radiotracer profiles. Oncogenic Kras and Apc loss showed the most distinctive imaging features, with [18F]FLT and [18F]FET being particularly effective, respectively. The tissue environment notably impacted [18F]FDG uptake, and in a metastatic model, [18F]FET demonstrated higher uptake.Conclusions:By examining factors contributing to PET-imaging phenotype, this study establishes the feasibility of noninvasive molecular stratification using multiplex radiotracer PET. It lays the foundation for further exploration of PET-based subtyping in human cancer, thereby facilitating noninvasive molecular diagnosis.

01 Jan 2024·European Journal of Nuclear Medicine and Molecular Imaging

Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model.

Article

Author: Böning, Guido ; Steiger, Katja ; Ziegler, Sibylle ; Meindl, Maria ; Bläske, Alexandra ; Port, Matthias ; Majewski, Matthäus ; von Ungern-Sternberg, Barbara ; Bartenstein, Peter ; Schüle, Simone ; Palumbo, Giovanna ; Oos, Rosel ; Lauber, Kirsten ; Lindheimer, Felix ; Lindner, Simon ; Brix, Nikko

AbstractPurposeA reliable method for regional in vivo imaging of radiation-induced cellular damage would be of great importance for the detection of therapy-induced injury to healthy tissue and the choice of adequate treatment of radiation emergency patients in both civilian and military events. This study aimed to investigate in a mouse model if positron emission tomography (PET) imaging with proliferation and apoptosis markers is potentially suitable for this purpose.MethodsFour groups, including twenty mice (wild-type C57BL/6) each, were whole-body irradiated with 0 Gy, 0.5 Gy, 1 Gy, and 3 Gy and examined by PET over a six-month period at defined time points. 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) and 2-(5-[18F]fluoropentyl)-2-methyl malonic acid ([18F]ML-10) were used to visualise proliferation and apoptosis. Regional standard uptake values were compared with respect to irradiation dose over time. Histologic data and peripheral blood cell values were correlated with the PET results.ResultsThe hematopoietic bone marrow showed a significantly increased [18F]FLT signal at early time points after radiation exposure (day 3 and day 7). This correlated with blood parameters, especially leukocytes, and histological data. A significantly increased [18F]FLT signal also occurred in the gastrointestinal tract and thymus at early time points. An increased [18F]ML-10 signal related to irradiation doses was observed in the bone marrow on day 8, but there was a high variability of standard uptake values and no correlation with histological data.Conclusion[18F]FLT showed potential to visualise the extent, regional distribution and recovery from radiation-induced cellular damage in the bone marrow, gastrointestinal tract and thymus. The potential of [18F]FLT imaging to assess the extent of bone marrow affected by irradiation might be especially useful to predict the subsequent severity of hematopoietic impairment and to adapt the therapy of the bone marrow reserve. [18F]ML-10 PET proved to be not sensitive enough for the reliable detection of radiation induced apoptosis.

01 Nov 2023·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

Author: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

100 Deals associated with Fluorothymidine F-18

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lymphoma	Phase 3	United States	National Cancer Institute	29 Sep 2008
Brain Cancer	Phase 2	United States	The Children's Hospital Corp.	01 Oct 2010
Breast Cancer	Phase 2	-	Merck Sharp & Dohme Corp.	08 Apr 2010
Breast Cancer 3	Phase 2	United States	National Cancer Institute	01 Dec 2008
Invasive Mammary Carcinoma	Phase 2	United States	National Cancer Institute	01 Dec 2008
Locally advanced breast cancer	Phase 2	United States	National Cancer Institute	01 Dec 2008
Laryngeal Neoplasms	Phase 2	United States	National Institutes of Health	01 Mar 2008
Mouth Neoplasms	Phase 2	United States	National Institutes of Health	01 Mar 2008
Oropharyngeal Neoplasms	Phase 2	United States	National Institutes of Health	01 Mar 2008
Squamous Cell Carcinoma of Head and Neck	Phase 2	United States	National Institutes of Health	01 Mar 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03276676 (CTgov)	Phase 1/2	Glioma \| Brain Cancer	10	[18F]Fluciclovine+[18F]FLT (Group A)	ochilaodwe(yoefiymfny) = plwbtbfdza vnkbommavl (spqfjqbxfn, mwoxfedqww - uygmxjmrdc) View more	-	27 Dec 2024
NCT03276676 (CTgov)	Phase 1/2	Glioma \| Brain Cancer	10	[18F]Fluciclovine+[18F]FLT (Group B)	ochilaodwe(yoefiymfny) = wbkkkgkwcr vnkbommavl (spqfjqbxfn, hsoihdrmme - oezzapljsi) View more	-	27 Dec 2024
NCT02392429 (CTgov)	Phase 2	Acute Myeloid Leukemia	87	Bone Marrow Biopsy+Fluorothymidine F-18+Cytarabine	ebxxmguvqz(oyvzafgbpd) = qyrjotumoc khrfuczfkc (vqhaxtfuqy, mpsrssbbff - hgppvijaps) View more	-	06 Aug 2024
NCT01244737 (CTgov)	Phase 2	Brain Cancer	50	[18F] FLT (New Diagnosis of Brain Tumor)	vhxpkobsvv(lrkeknpgsg) = byawwxmhvc vckirgminb (eivexpsalw, egltndjlev - rjgmunjgkl) View more	-	11 Jul 2024
NCT01244737 (CTgov)	Phase 2	Brain Cancer	50	[18F] FLT (Possible Recurrent Brain Tumor)	vhxpkobsvv(lrkeknpgsg) = inikjssjtl vckirgminb (eivexpsalw, uhqyxjsxkt - dfipalekxv) View more	-	11 Jul 2024
NCT03318497 (CTgov)	Phase 2	Pancreatic adenocarcinoma	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(gfjnwortcf) = zbhxzjtxxm ymnleuynjb (pxjwydmtaz, pqdtayqhyq - okmeiaylfc) View more	-	08 Nov 2022
NCT01399658 (AMIGO, CTgov)	Phase 2	Vagina Carcinoma \| Uterine Cervical Cancer \| Vulvar Neoplasms	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	eypzrdolgl(xhguxeqfnh) = fbjaduaquu deaukpmpxn (kuytrrxydl, eoyodtwahe - klyjtoawoi) View more	-	02 Mar 2022
EANM2021	Not Applicable	Ki-67	-	18 F-fluorothymidine (Non-irradiation group)	obzekjfssa(vsisydjdsl) = jvktuefouq ueknyoycbn (iqkrtzktoo ) View more	-	24 Sep 2021
EANM2021	Not Applicable	Ki-67	-	18 F-fluorothymidine (Irradiation group)	obzekjfssa(vsisydjdsl) = youlezsoxk ueknyoycbn (iqkrtzktoo ) View more	-	24 Sep 2021
NCT00979810 (CTgov)	Not Applicable	High grade glioma	11	18F-FLT PET Scan	upyqiecngr(fhrytpjhqj) = bwwwhmumam wbenriwtym (diybwgywca, jggmpbswtz - zapwlvqlgf) View more	-	17 Dec 2020
EANM2019	Not Applicable	-	-	18 F-FLT	gauojysfsf(zfmkkslyvj) = few cqkkwozmzu (ikngfqgazb ) View more	-	18 Sep 2019
EANM2019	Not Applicable	-	-	18 F-FLT (N-BOC-FLT)		-	18 Sep 2019
ISC2019	Not Applicable	Ischemic stroke Ki67	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	tnggxdkbtp(cvyyfmhwfr) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain klkxecqigb (zoykutnvvr ) View more	-	01 Feb 2019
NCT00721799 (CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck \| Laryngeal Neoplasms \| Oropharyngeal Neoplasms \| Mouth Neoplasms	33	18F-Fluorothymidine PET scan	tnpltexvnm(phffkybejo) = duuftzbvdo xxfuswckfy (nbpgkdshfe, yjriizsbmj - xaywcgpbvy) View more	-	03 Oct 2017